EUVIMEDEUVIMED entdecken
Open Access

In Silico Analysis of Enantioselective Binding of Pomalidomide Targets for Multiple Myeloma

Gyan Vardhan, Vikas Kumar iD, Ashish Kumar, Shailendra Handu, Puneet Dhamija iD

Chirality · 2026-08 · 38 (8)

DOI: 10.1002/chir.70125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chirality, online erschienen am 18.07.2026. Verfasst von Gyan Vardhan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India. Hauptthemen laut MEDLINE: Thalidomide, Multiple Myeloma. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pomalidomide is a 2nd‐generation chiral immunomodulatory (IMiDs) drugs and have antiangiogenic activity. Despite being teratogenic, it has been shown to be effective in treating multiple myeloma. Enantioselectivity, chemical structure, and biological activity have been investigated using molecular docking. In silico docking simulations to confirm the enantioselective binding of pomalidomide to immunomodulator targets, namely, CRBN, TNF‐ α11, Pg G/H synthase 2, and Cadeherin‐5 Protein. The protein was preprocessed using hydrogen addition, disulphide treatment, and bond order assignment. The Ligand Preparation Module was used to optimize all of the chosen ligands, and OPLS3e Forcefield was used to optimize the geometry. Site map analysis module was used to determine the top‐ranked receptor binding sites for the enzymes. Molecules were docked by using Schrodinger 2020_3 software. Docking study confirms the enantioselective binding of pomalidomide to immunomodulator targets (CRBN, TNF‐α_11, Pg G/H synthase 2, and Cadeherin‐5 Protein). Out of all four targets S‐ (−) enantiomer of pomalidomide had significant binding with CRBN and TNF‐α 11, while R‐(+)enantiomer of pomalidomide had significant binding with Pg G/H synthase 2, and Cadeherin‐5 Protein. The result suggests that, chemical interactions of S‐enantiomer of pomalidomide have better binding with residues at the active site of CRBN and TNF‐α 11 . This concludes that S‐enantiomer of pomalidomide could be a better choice for multiple myeloma therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThalidomideMultiple MyelomaStereoisomerismMolecular Docking SimulationHumansBinding SitesProtein BindingComputer Simulation

Stichwörter der Autor:innen

chiralitydockingenantiomersmultiple myelomapomalidomide

Substanzen

Thalidomidepomalidomide

Autor:innen und Institutionen

  • Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
  • Department of Pharmacology, All India Institute of Medical Sciences, Bathinda, Punjab, India.

ORCID-Profile: Vikas Kumar, Puneet Dhamija

Zitieren

APA

Vardhan, G., Kumar, V., Kumar, A., Handu, S., & Dhamija, P. (2026). In Silico Analysis of Enantioselective Binding of Pomalidomide Targets for Multiple Myeloma. Chirality, 38(8). https://doi.org/10.1002/chir.70125

Vancouver

Vardhan G, Kumar V, Kumar A, Handu S, Dhamija P. In Silico Analysis of Enantioselective Binding of Pomalidomide Targets for Multiple Myeloma. Chirality. 2026;38(8). doi:10.1002/chir.70125

BibTeX
@article{Vardhan2026,
  author = {Vardhan, Gyan and Kumar, Vikas and Kumar, Ashish and Handu, Shailendra and Dhamija, Puneet},
  title = {In Silico Analysis of Enantioselective Binding of Pomalidomide Targets for Multiple Myeloma},
  journal = {Chirality},
  year = {2026},
  volume = {38},
  number = {8},
  doi = {10.1002/chir.70125}
}
Kostenlos starten →